Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28266606
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in
Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
#MMPMID28266606
Qiu Q
; Huang J
; Shu X
; Fan H
; Zhou Y
; Xiao C
Sci Rep
2017[Mar]; 7
(?): 44015
PMID28266606
show ga
Methotrexate (MTX) is widely used and considered a first-line disease modifying
anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Many
of the relevant genes have been investigated to estimate the association between
gene polymorphisms and MTX effectiveness in RA patients, although inconsistent
results have been reported. A systematic review and meta-analysis were performed
to identify genetic variants associated with MTX efficacy. A total of 30
publications that included 34 genes and 125 SNPs associated with the
transporters, enzymes, and metabolites of MTX or the progression of RA were
included in the systematic review (SR), and 21 studies were included in 9
meta-analyses. Associations between MTX response in RA patients in MTHFR
1298A?>?C (rs1801131), ATIC 347C?>?G (rs2372536), RFC-1 80G?>?A (rs1051266),
SLC19A1 A?>?G (rs2838956) and SLC19A1 G?>?A (rs7499) genetic polymorphisms were
found, but not observed between the MTHFR 677C?>?T (rs1801133), TYMS 28?bp VNTR
(rs34743033), MTRR 66A?>?G (rs1801394), and ABCB1 3435C?>?T (rs1045642). However,
for the polymorphisms not being associated following meta-analysis could still be
associated if larger cohorts were used, and studies of other polymorphisms are
necessary in large cohorts and a rigorous way, which may provide more accurate
results for the effect of the gene polymorphisms on the MTX response.
free
free
free
